Spotlight on brodalumab in the treatment of moderate-to-seve…

Established

40

Citations

46

Refs

2017

Year

Search Works

Work Details

DOI 10.2147/dddt.s113683
PMID https://pubmed.ncbi.nlm.nih.gov/28744098
PMCID https://www.ncbi.nlm.nih.gov/pmc/articles/5511025
OpenAlex ID W2732144268
Type Review
Language EN
Published 01 Jul 2017
Volume Volume 11
Pages 2065–2075
Source Drug Design Development and Therapy
Publisher Dove Medical Press
FWCI 0.42
Countries 1
Institutions 1
Added 14 Jul 2017
Updated 31 Oct 2026

External Links

OpenAlex Record DOI Resolver PubMed PubMed Central PDF

Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy

Review 2017 EN Gold

Abstract: Brodalumab is a novel fully human immunoglobulin G2 monoclonal antibody that antagonizes the interleukin (IL)-17 pathway by binding with high affinity to human IL-17RA. The role of IL-17A in the pathogenesis of psoriasis, as well as the remarkable effectiveness of IL-17 inhibitors in the treatment of moderate-to-severe plaque psoriasis, is well established. The mechanism of action of bro…

40

Citations

46

References

2

Authors

0.42

FWCI

Citations by Year

Last 9 years

Topics

Keywords

UN Sustainable Development Goals

1 SDGs

Authors & Affiliations

2 authors

#	Author	Institutions	ORCID
1	Michael Roman	University of California, Los … (US)
2	Melvin W. Chiu Corresponding	University of California, Los … (US)

Related Works

Data: OpenAlex